Breaking down the multidimensional relationship between obesity and breast cancer reveals a matrix of clinical, molecular, and epidemiological facets. As a major public health challenge spanning continents—from Asia to North America, Europe, and beyond—obesity is recognized for contributing to multiple cancers. The escalating rates of obesity, fueled by shifts in nutrition and lifestyle, demand urgent investigation into how excess adiposity modulates breast cancer risk, treatment response, and prognosis. These intricacies are compounded by discrepancies in obesity assessment methods, which have fueled conflicting epidemiological findings, particularly when differentiating breast cancer risk between premenopausal and postmenopausal women.

Diving into diagnostic criteria exposes an array of heterogeneity that muddies the water of breast cancer risk evaluation. Body Mass Index (BMI), waist circumference, and other anthropometric markers vary not only across populations but also in their predictive power for breast cancer subtypes. This review synthesizes evidence from domestic and international studies, elucidating how obesity’s impact diverges depending on menopausal status, reinforcing the necessity for refining obesity definitions in research and clinical practice. Premenopausal women often display paradoxical trends where obesity may not correlate strongly with increased breast cancer risk, while postmenopausal women show a clearer risk elevation associated with adiposity, underscoring a nuanced biological interplay orchestrated by hormonal and metabolic pathways.

At the forefront of this discourse lies the complex molecular tapestry connecting obesity and breast cancer. Genetic factors such as the fat mass and obesity-associated gene (FTO) have been implicated in adiposity-linked carcinogenesis. FTO’s role extends beyond energy homeostasis, influencing oncogenic signaling and tumor progression. Meanwhile, adipokines—the bioactive proteins secreted by adipose tissue—further modulate the tumor microenvironment. Leptin, resistin, and visfatin emerge as potent pro-inflammatory and mitogenic agents exacerbating cancer cell proliferation and invasion, whereas adiponectin typically confers protective effects. This dynamic balance of adipokines shapes not only cancer initiation but also metastatic potential.

Estrogen metabolism, a cornerstone of breast cancer pathophysiology, is significantly altered in the context of obesity. Excess adipose tissue serves as a reservoir for aromatase, an enzyme catalyzing the conversion of androgens to estrogens. This heightened estrogen synthesis, especially in postmenopausal women where ovarian production wanes, fuels hormone-sensitive tumor growth. The interplay between obesity-induced estrogen surges and receptor-positive breast cancers illustrates a pivotal axis through which adiposity exacerbates oncogenic risk, emphasizing the importance of hormonal milieu in tumor dynamics.

The investigation extends to chronic inflammation, a recognized hallmark of obesity and cancer. Adipose tissue dysfunction leads to the secretion of pro-inflammatory cytokines like interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). These inflammatory mediators orchestrate a microenvironment conducive to DNA damage, immune evasion, and angiogenesis within breast tissue. The crosstalk between inflammatory pathways and cancer cells fosters a vicious cycle promoting tumor initiation, progression, and resistance to therapy.

Intricately tied to inflammation and hormonal effects is the remodeling of the tumor microenvironment. Obesity reshapes this ecosystem, involving cancer-associated adipocytes (CAAs), extracellular matrix (ECM) modifications, and emerging roles of the microbiota. CAAs, once viewed as passive fat stores, actively secrete growth factors and matrix metalloproteinases that facilitate tumor invasion and metastasis. Concurrently, ECM remodeling alters tissue stiffness and architecture, influencing tumor cell behavior and drug delivery. Additionally, emerging research highlights that obesity-associated dysbiosis in tissue and gut microbiomes may influence inflammatory and immune responses, adding another layer to the obesity-breast cancer nexus.

Clinically, obesity compounds challenges in breast cancer management. Patients with obesity often experience delayed diagnosis due to screening difficulties and reduced sensitivity of mammographic imaging. Moreover, pathological features tend to be more aggressive, with higher-grade tumors and increased lymphovascular invasion being more prevalent. These unfavorable characteristics correlate with poorer prognosis, higher rates of recurrence, and reduced survival outcomes, emphasizing the urgency of addressing obesity within oncological care paradigms.

Treatment complexities further unfold as obesity influences therapeutic response. Altered pharmacokinetics and pharmacodynamics in obese patients can affect drug efficacy and toxicity profiles. Hormonal therapies, chemotherapy, and radiation treatments may demonstrate variable success in overweight populations, necessitating tailored dosing strategies. Furthermore, obesity-induced chronic inflammation and metabolic dysregulation may promote resistance mechanisms, challenging existing therapeutic regimes and highlighting the need for integrated approaches.

The translational potential of these insights draws attention to innovative strategies aimed at mitigating obesity’s impact on breast cancer. Lifestyle interventions encompassing nutrition, physical activity, and behavioral modifications remain foundational but are often limited by sustainability and patient adherence. Pharmacological avenues targeting adipokines, inflammatory mediators, or metabolic pathways represent promising adjuncts but require further clinical validation. In this landscape, bariatric metabolic surgery emerges as a groundbreaking modality with potential benefits beyond weight loss.

Bariatric surgery holds multifaceted promise in reshaping breast cancer outcomes for patients with obesity. By inducing sustained weight reduction, it alters hormonal, inflammatory, and metabolic profiles, potentially lowering breast cancer incidence and improving prognosis. Early studies reveal favorable shifts in adipokine levels, decreased aromatase activity, and diminished systemic inflammation post-surgery. Furthermore, metabolic surgery may enhance treatment responsiveness and lower recurrence risk, positioning it as a potent adjunct in breast cancer management.

The convergence of lifestyle, pharmacological, and surgical interventions embodies a holistic approach to addressing obesity within oncology. Personalized treatment plans that integrate these elements can optimize therapeutic efficacy while minimizing adverse effects. As research advances, the prospect of harnessing multidimensional interventions to break the obesity-breast cancer link grows increasingly tangible, offering hope for improved patient outcomes on a global scale.

Advancements in molecular profiling and biomarkers will further elucidate patient-specific risk stratification and treatment tailoring. Integration of genetic screening for obesity-related oncogenes such as FTO, alongside metabolic and inflammatory markers, may refine early detection and therapeutic targeting. This precision oncology approach, coupled with population-level strategies to curb obesity rates, could revolutionize breast cancer prevention and care in the coming decades.

In essence, the complex interplay between obesity and breast cancer transcends simple cause-effect relationships, encompassing genetic, biochemical, and environmental dimensions. Recognizing and dissecting these layers is imperative in tackling one of the most pressing health issues of our time. The narrative is no longer just about excess weight but about its profound and multifarious impact on breast cancer’s epidemiology, biology, and clinical trajectory.

Future directions beckon multidisciplinary collaboration bridging oncology, endocrinology, immunology, and surgery. This integrated perspective, supported by rigorous research and innovative therapies, holds the key to unlocking countermeasures against obesity-driven breast cancer. As the global burden of obesity escalates, so must our urgency and ingenuity in addressing its role in one of women’s deadliest diseases.

Through comprehensive understanding and intervention, the grim statistics of breast cancer incidence and mortality intertwined with obesity may be rewritten. Empowering patients with personalized, multidimensional strategies heralds a new era where obesity no longer tips the scales against women’s health, but rather becomes a modifiable facet within the broader conquest of breast cancer.

Subject of Research:
The impact of obesity on breast cancer incidence, treatment outcomes, and prognosis, with detailed exploration of underlying molecular mechanisms and clinical implications.

Article Title:
Multidimensional Risk Impact of Obesity on Breast Cancer Incidence, Treatment, and Prognosis.

Article References:
Liu, Y., Xu, S., Yang, H. et al. Multidimensional risk impact of obesity on breast cancer incidence, treatment, and prognosis. Int J Obes (2026). https://doi.org/10.1038/s41366-025-02008-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-02008-9

Keywords:
Breast cancer, obesity, adipokines, FTO gene, estrogen metabolism, chronic inflammation, tumor microenvironment, cancer-associated adipocytes, bariatric surgery, epidemiology

Body mass index, a widely recognized indicator of body fat, serves as a key measure in epidemiological studies. Obesity has long been implicated in the development of various metabolic disorders, including impaired fasting glucose, a precursor to Type 2 diabetes. What makes this study particularly interesting is the focus on the neutrophil-to-lymphocyte ratio, a biomarker that reflects systemic inflammation often overlooked in dietary and lifestyle-related health assessments. Recognizing the intersection of these variables opens new avenues for research and potential interventions.

The research team meticulously recruited participants and tracked their health metrics over five years. This longitudinal approach offers a richer understanding of the dynamics at play—unlike cross-sectional studies that provide only a snapshot. Long-term data allow researchers to observe trends and associations over time, making the results more robust and compelling. The study involved assessing participants’ BMI, NLR, and fasting glucose levels, capturing a comprehensive picture of their health progression.

Initial findings revealed a notable correlation between increased BMI and elevated NLR levels, indicating that overweight and obese individuals tend to exhibit a heightened inflammatory response. This is particularly crucial as chronic inflammation is a known factor contributing to insulin resistance and impaired glucose metabolism. The data suggests that as individuals gain weight, their immune response may shift in ways that directly impact their ability to regulate blood sugar levels adequately.

What’s particularly novel about these findings is the mediating role of BMI in the relationship between NLR and impaired fasting glucose. Essentially, the data indicates that NLR does not directly initiate impaired glucose response; instead, it is the individual’s BMI that amplifies this association. Understanding this mediation can radically alter prevention strategies for those at risk of developing diabetes. It suggests that targeting body weight might mitigate the adverse effects of inflammation on glucose metabolism more effectively than previously thought.

The implications of this research extend beyond academic interest; they hold the potential to influence public health strategies. With rates of obesity escalating globally, understanding the biological mechanisms at play is critical for developing targeted interventions. For instance, lifestyle modifications aimed at weight reduction, such as improved dietary habits and increased physical activity, could diminish inflammation and therefore improve metabolic outcomes.

In analyzing the data, Liu and colleagues employed advanced statistical methods to ensure the accuracy and reliability of their findings. Through regression models, they were able to control for various confounding factors such as age, gender, and lifestyle, thus isolating the effects of BMI and NLR on fasting glucose levels. Such rigorous methodologies lend credibility to their conclusions and pave the way for further investigations into the links between inflammation and metabolic disorders.

Interestingly, the study also highlights the potential of NLR as a simple, cost-effective marker for identifying individuals at higher risk of metabolic diseases. As NLR can be derived from routine blood tests, it presents a feasible option for healthcare providers seeking to implement early intervention strategies. By identifying at-risk populations through NLR measurements, targeted lifestyle changes could be recommended, effectively disrupting the cycle before glucose impairment manifests.

The five-year follow-up provided not only insight into treatment efficacy but also brought forth questions about the reversibility of impaired glucose states. Can reduced inflammation through weight loss lead to normalized glucose levels? The evidence suggests a promising possibility. Participants who successfully lowered their BMI also experienced significant reductions in NLR and improvements in fasting glucose levels, hinting at the body’s remarkable ability to heal when faced with lifestyle changes.

As the scientific community aims to combat the burgeoning diabetes epidemic, studies such as these are invaluable. They underscore the importance of a multifaceted approach that considers not only weight management but also the inflammatory pathways that contribute to disease. By integrating this knowledge into clinical practice, healthcare professionals can offer more comprehensive care for patients struggling with obesity and metabolic dysfunction.

Lastly, as this research garners attention, it encourages further exploration into additional biomarkers that may interact with BMI and metabolic health. Future studies could expand on these findings by incorporating genetic, environmental, and lifestyle factors, creating a more exhaustive profile of what influences fasting glucose levels. The quest to understand and manage diabetes is far from over, and investigations such as the one conducted by Liu, Wu, and Peng are pivotal stepping stones toward holistic health solutions.

In summary, Liu et al.’s findings present a clear message: managing body weight is not just about aesthetics; it plays a critical role in our overall metabolic health. With a focus on inflammation as a key player in this narrative, the research opens exciting avenues for potential interventions. As we move forward, adopting a more integrated approach to tackling obesity could serve as an effective strategy in reducing the burden of diabetes and improving public health outcomes at large.

Subject of Research: The mediation effect of body mass index on the relationship between neutrophil-to-lymphocyte ratio and impaired fasting glucose.

Article Title: Body mass index mediates the association between neutrophil-to-lymphocyte ratio and impaired fasting glucose: evidence from a five-year follow-up study.

Article References: Liu, Y., Wu, B., Peng, G. et al. Body mass index mediates the association between neutrophil-to-lymphocyte ratio and impaired fasting glucose: evidence from a five-year follow-up study.
Sci Rep (2026). https://doi.org/10.1038/s41598-025-34721-w

Image Credits: AI Generated

DOI: 10.1038/s41598-025-34721-w

Keywords: Body mass index, neutrophil-to-lymphocyte ratio, impaired fasting glucose, inflammation, metabolic health.

Ultra-processed foods, characterized by industrial formulations typically high in sugars, unhealthy fats, and additives, have increasingly been scrutinized for their contribution to the burgeoning rates of obesity worldwide. While epidemiological studies routinely associate high UPF consumption with excess body weight, a perplexing observation persists: not all individuals consuming greater amounts of UPFs develop obesity. This heterogeneity has propelled researchers to hypothesize a modifying role of genetic susceptibility, yet empirical evidence integrating precise genetic risk measurements with long-term dietary intake in childhood has been scarce—until now.

Drawing on the rich, longitudinal data of the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort in England, researchers examined over 3,000 participants who were followed meticulously from age 7 through 24. The study uniquely quantified UPF intake at age 7 through comprehensive food diaries categorized using the rigorous NOVA classification system, which stratifies foods based on their level of processing. Simultaneously, the genetic predisposition to obesity was quantified by constructing a polygenic score (PGS) for body mass index, utilizing cutting-edge algorithms such as LDpred2 for high-resolution risk prediction. This multidimensional approach allowed for unprecedented insights into how diet and genetics interplay over nearly two decades.

The findings are both compelling and intricate. Statistical modeling revealed that for every 10% increase in total energy intake sourced from UPFs at age 7, there was a corresponding increase of 0.21 kg/m² in BMI by age 24. This association remained robust even after adjusting for potential confounders including physical activity, socioeconomic status, baseline BMI, and overall energy intake levels—underscoring the independent deleterious impact of UPFs on long-term adiposity. However, this average effect masks a revealing interaction with genetic risk.

When dissecting the data by genetic susceptibility tiers, an unexpected pattern emerged. The positive association between childhood UPF consumption and early-adulthood obesity was significantly amplified only in individuals within the highest decile of BMI polygenic scores. For these genetically predisposed children, a 10% increase in energy from UPFs translated into a striking 0.74 kg/m² increase in BMI at 24, a magnitude roughly triple the average effect size observed across the entire cohort. Conversely, children with lower genetic risk showed no significant association, suggesting their metabolic resilience or alternative compensatory mechanisms against the obesogenic effects of ultra-processed diets.

This gene-diet interaction hypothesis carries profound implications for precision nutrition in pediatric populations. It suggests that blanket dietary guidelines—while beneficial—may fail to address individual vulnerabilities that stem from inherited genetic architecture. The findings advocate for incorporating polygenic risk scoring into early-life dietary assessments, empowering clinicians and public health practitioners to tailor interventions that prioritize restricting UPF intake among genetically susceptible children, potentially staving off lifelong obesity trajectories.

Understanding the mechanisms linking UPF consumption to obesity and their modification by genetics requires delving into diet-induced alterations in metabolism and gene expression. Ultra-processed foods, often hyper-palatable and energy-dense, may promote excessive caloric ingestion and metabolic dysregulation. In genetically predisposed individuals, variations in genes regulating appetite, fat storage, and energy expenditure might exacerbate the response to such diets, leading to a convergence of environmental and biological drivers of adiposity. Future research integrating genomics, epigenetics, and metabolomics could elucidate these pathways, offering new therapeutic targets.

The study also highlights the unique advantage of longitudinal cohort designs in unpacking complex chronic disease etiologies. By capturing dietary behaviors in early childhood and linking them with adult health outcomes while controlling for baseline confounders, the research delineates a temporal and potentially causal relationship rather than mere cross-sectional associations. The application of state-of-the-art genetic scoring methods further strengthens causal inference, positioning this work at the vanguard of nutritional epidemiology.

Beyond academic significance, these findings resonate with societal and policy-level priorities. The ubiquity and aggressive marketing of ultra-processed foods to children raise concerns about exposing vulnerable populations to early risk factors for obesity and associated comorbidities such as diabetes and cardiovascular disease. Policies aimed at reducing children’s access to UPFs and promoting whole, minimally-processed foods could have disproportionate benefits in genetically high-risk subgroups, amplifying public health impact.

Importantly, while the study was rigorously conducted in a UK-based cohort with predominantly European ancestry, generalizability to more diverse populations warrants further exploration. Genetic architecture and dietary patterns vary globally; thus, replication studies in different ethnic and socioeconomic contexts are crucial to validate and extend these findings. Moreover, the reliance on food diaries, while comprehensive, introduces potential reporting biases that future research could mitigate using objective biomarkers of dietary intake.

Ethical considerations arise when integrating genetic risk profiling into pediatric nutrition counseling. Issues of consent, data privacy, and potential stigmatization must be addressed transparently. Nonetheless, the promise of personalized preventive strategies that could transform childhood obesity prevention justifies advancing this research agenda with careful safeguards and equity-focused frameworks.

In summation, this pioneering study compellingly demonstrates that the adverse impact of ultra-processed food consumption on obesity risk is not uniform across children but is significantly modulated by inherited genetic susceptibility. Such gene-environment interplay underscores the necessity of moving beyond “one-size-fits-all” recommendations towards dynamic, individualized nutrition strategies to curb the obesity epidemic effectively. As the science of nutrigenomics matures, integrating genetic risk with lifestyle factors promises a new era of tailored preventive medicine.

Looking forward, future investigations should strive to untangle the interactions of UPFs with other genetic and epigenetic factors, explore mechanisms underlying metabolic resilience in low-risk individuals, and test the efficacy of genotype-informed dietary interventions in randomized controlled trials. Such endeavors will propel public health into a future where early, precise, and personalized actions can alter the course of non-communicable diseases worldwide.

The emergent narrative from this research illuminates the convergence of modern genomic science with classical nutritional epidemiology, breaking new ground in understanding how early dietary exposures and inherited biology coalesce to shape lifelong obesity risk. This synergy provides a powerful framework for researchers, clinicians, and policymakers grappling with one of the most pressing health crises of our time.

Subject of Research: Childhood ultra-processed food consumption, genetic susceptibility, and obesity risk in early adulthood.

Article References:
Abstracts from the 10th meeting of the Association for the Study of Obesity: UK Congress on Obesity 2025.
Int J Obes 49 (Suppl 1), 1–45 (2025). https://doi.org/10.1038/s41366-025-01880-9

Image Credits: AI Generated

A groundbreaking study recently published in the International Journal of Obesity by Liu and colleagues sheds new light on this complex association by investigating not just the epidemiological correlations but also the underlying molecular mechanisms that potentially bind childhood obesity to adult cholelithiasis. Utilizing advanced transcriptomic analyses, the research team embarked on an exploratory journey to decode the shared biological pathways that may underlie this relationship. This novel approach transcends traditional epidemiological assessments by integrating gene expression profiles, thereby providing a more mechanistic insight into the developmental origins of gallstone disease.

The study meticulously stratified obesity records according to specific childhood age brackets, uncovering that exposure to obesity during distinct developmental windows might differentially influence the risk trajectory for cholelithiasis in adulthood. This age-specific analytical framework challenges the conventional notion that childhood obesity is a singular risk factor, emphasizing instead that the timing of obesity onset may be pivotal in shaping long-term gallstone susceptibility. Through this lens, it becomes evident that early intervention strategies must be finely tuned not only to reduce obesity prevalence but also to target the precise periods of vulnerability during childhood.

Delving deeper, the authors employed transcriptomic techniques to analyze liver tissue samples and blood specimens, seeking patterns of gene expression that correlate with both childhood obesity and adult gallstone formation. This multi-layered molecular profiling revealed a suite of shared gene expression signatures, predominantly associated with lipid metabolism, bile acid synthesis, and inflammatory signaling pathways. These findings underscore the intertwined nature of metabolic dysfunction and immune response in orchestrating the pathogenesis of cholelithiasis in individuals who experienced obesity early in life.

One particularly notable insight from the transcriptomic data was the dysregulation of genes involved in cholesterol homeostasis. Since cholesterol supersaturation of bile is a well-established precursor to gallstone formation, the observation that childhood obesity imprints lasting changes on genes regulating cholesterol transport and metabolism suggests a biological conduit linking early-life metabolic disturbances to adult gallstone disease risk. This revelation opens promising avenues for therapeutic targeting, as modulating cholesterol-related pathways could potentially mitigate the progression of gallstone formation in at-risk populations.

Moreover, the study unearthed alterations in genes implicated in bile acid cycling, a critical determinant of gallstone pathophysiology. Bile acids not only facilitate fat digestion but also act as signaling molecules modulating metabolic and inflammatory processes. By demonstrating that childhood obesity is associated with persistent transcriptomic shifts in bile acid-related genes, the research highlights a plausible mechanism where early-life adiposity disrupts bile acid homeostasis, thereby contributing to a pro-cholelithogenic milieu in adulthood.

Inflammation, an increasingly recognized culprit in metabolic diseases, was also spotlighted in the findings. The team observed that obesity during pivotal stages of childhood development amplifies the expression of proinflammatory genes, which may exacerbate biliary tract inflammation and promote gallstone genesis. This inflammatory component suggests that immune modulation could constitute an adjunctive strategy for preventing gallstone disease among individuals with a history of pediatric obesity.

Importantly, the researchers’ transcriptomic approach illustrates the enduring nature of obesity-induced molecular imprinting. Such epigenetic and gene expression modifications, established during critical windows of growth, appear to predispose individuals to metabolic diseases far beyond the initial period of increased adiposity. This concept of a ‘metabolic memory’ amplifies the urgency for early prevention, as the biological consequences of childhood obesity might be far harder to reverse once entrenched.

The implications of these findings extend beyond basic science, hinting at a future where diagnostic tools could integrate transcriptomic biomarkers to identify children at greatest risk for adult gallstone disease. Such precision medicine approaches could revolutionize screening protocols and allow for timely interventions tailored to individual biological profiles. Furthermore, this research advocates for a paradigm shift in public health, emphasizing the prevention of obesity not solely as a means to address immediate health impacts but also to curtail chronic metabolic sequelae that manifest decades later.

Conceptually, the study by Liu et al. propels the field toward a unified model that accounts for both environmental exposures—such as nutritional excess and sedentary behavior—and inherent molecular susceptibilities shaped during childhood obesity. It harmonizes epidemiology and molecular biology, demonstrating that the path to adult cholelithiasis is paved with biological changes etched early in life. Understanding this trajectory enables researchers to hypothesize novel interventions that disrupt this progression, potentially through diet modification, pharmacotherapy targeting bile acid pathways, or anti-inflammatory treatments during childhood.

In addition to its scientific contributions, this research invigorates the dialogue around childhood health policies. Given that gallstone disease imposes significant clinical and economic burdens globally, elucidating modifiable risk factors with molecular specificity can empower policymakers to craft age-tailored obesity prevention campaigns. Implementing such strategies in schools and communities could diminish the future prevalence of gallstone disease, translating into improved quality of life and reduced healthcare expenditures.

Beyond the immediate focus on cholelithiasis, these insights hold broader relevance for other obesity-associated metabolic disorders. The shared transcriptomic bases implicated here may also underlie susceptibility to conditions like non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular diseases, all of which are linked to obesity in early life. This suggests that interventions designed to recalibrate the implicated pathways might yield multifaceted benefits, amplifying the public health impact.

Challenges remain, however, in translating these transcriptomic discoveries into clinical practice. Variations in gene expression may be influenced by complex factors including genetic background, environmental exposures, and lifestyle choices, underscoring the need for large-scale, longitudinal studies to validate these initial findings across diverse populations. Moreover, ethical considerations around genetic testing in children warrant careful deliberation to balance benefits against potential risks.

Nevertheless, the study’s innovative integration of age-specific obesity data and transcriptomic analysis represents a watershed moment in understanding the biological legacy of childhood adiposity. It sets the stage for future research to unravel further molecular intricacies, refine risk prediction models, and ultimately foster interventions that can intercept the trajectory from childhood obesity to adult gallstone disease.

In conclusion, the comprehensive exploration by Liu and colleagues marks a critical advance in the obesity research landscape. By illuminating both the epidemiological associations and shared molecular underpinnings between childhood obesity and adult cholelithiasis, this work not only enhances scientific understanding but also charts an actionable path toward disease prevention. As obesity continues to challenge global health systems, such integrative approaches offer hope for stemming the tide of chronic metabolic illnesses rooted in early life.

Subject of Research: The causal relationship between age-specific childhood obesity and adult cholelithiasis, with emphasis on shared transcriptomic bases.

Article Title: Age-specific childhood obesity and adult cholelithiasis: association and shared transcriptomic bases.

Article References:
Liu, L., Zhang, L., Liao, Y. et al. Age-specific childhood obesity and adult cholelithiasis: association and shared transcriptomic bases. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01877-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01877-4